10 Important GLP-1 Contraindications You Should Be Aware Of

GLP-1 contraindications include a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2 (MEN2), and serious allergic reactions to certain GLP-1 medications.

Other important safety concerns include pregnancy, pancreatitis, gastroparesis, gallbladder disease, dehydration-related kidney injury, hypoglycemia, and diabetic retinopathy.

Although not all these conditions are absolute contraindications, they can affect whether medications such as Ozempic, Wegovy, Mounjaro, or Zepbound are appropriate. Understanding these risks helps patients make informed treatment decisions with their healthcare providers.

DFWPMA offers in-person GLP-1 prescription evaluations in Texas and can prescribe GLP-1 medications at a DFWPMA location across Texas to eligible patients when medically appropriate, subject to medication availability.

Our primary care providers and endocrinologists also offer ongoing care to monitor potential side effects, address health concerns, and support patients throughout GLP-1 treatment. DFWPMA does not currently offer online GLP-1 prescriptions, an in-person evaluation is required.

Book an appointment online or call (903) 957-0082 to contact our scheduling team.

Get Prescriptions for GLP-1 Medications at a DFWPMA Location Near You!

📍 GLP-1 Prescription Providers in Fort Worth, TX

1220 W Presidio St, Fort Worth, TX 76102

Book an Appointment at Our Fort Worth Location →
📍 GLP-1 Prescription Providers in Frisco, TX

7589 Preston Rd., Suite 900, Frisco, TX 75034

Book an Appointment at Our Frisco Location →
📍 GLP-1 Prescription Providers in Sherman, TX

425 N Highland Ave., Suite 260, Sherman, TX 75092

Book an Appointment at Our Sherman Location →
📞 Call DFWPMA to Schedule

Speak with our scheduling team about GLP-1 prescription evaluations, provider availability, and appointments.

Call Us → (903) 957-0082

We accept many major insurance plans. Not sure if your plan is accepted?

Call (903) 957-0082 and our team can help verify coverage.

Contraindication #1: Personal or Family History of Medullary Thyroid Cancer

What Is Medullary Thyroid Cancer?

Medullary thyroid cancer (MTC) is a rare form of thyroid cancer that develops in the thyroid’s hormone-producing C cells. A personal or family history of MTC is an absolute contraindication to several GLP-1 medications, including semaglutide and tirzepatide, because these medications have caused thyroid C-cell tumors in animal studies. Whether they cause MTC in humans remains unknown.

Potential Consequences of Taking GLP-1 Medications with This Condition

Using a GLP-1 medication despite a personal or family history of medullary thyroid cancer violates an established medication contraindication. Although an increased risk of MTC in humans has not been demonstrated, the potential concern is serious enough that affected patients should avoid medications carrying this warning. Important warning signs of thyroid tumors include:

  • Neck Lump: A new or enlarging mass in the neck may indicate an underlying thyroid tumor.
  • Difficulty Swallowing: An enlarging thyroid tumor may interfere with normal swallowing.
  • Persistent Hoarseness: Changes in the voice may develop when a thyroid tumor affects nearby structures.
  • Breathing Difficulties: A sufficiently large thyroid tumor may compress the airway.
  • Delayed Cancer Diagnosis: Ignoring suspicious thyroid symptoms may delay evaluation and treatment of an existing malignancy.

Contraindication #2: Multiple Endocrine Neoplasia Syndrome Type 2 (MEN2)

What Is Multiple Endocrine Neoplasia Syndrome Type 2?

Multiple endocrine neoplasia syndrome type 2 (MEN2) is an inherited genetic condition associated with a high risk of medullary thyroid cancer and certain other endocrine tumors. MEN2 is an absolute contraindication to several GLP-1 medications, including semaglutide and tirzepatide, regardless of whether thyroid cancer has already developed.

Potential Consequences of Taking GLP-1 Medications with This Condition

Patients with MEN2 already have an inherited predisposition to developing endocrine tumors. Taking a GLP-1 medication carrying an MEN2 contraindication introduces an avoidable, uncertain medication-related thyroid tumor concern. The following complications are associated with MEN2 itself and illustrate why recognizing the condition is essential:

  • Medullary Thyroid Cancer: MEN2 substantially increases the lifetime risk of developing this thyroid malignancy.
  • Pheochromocytoma: Adrenal tumors may release excessive catecholamines and cause dangerous blood pressure elevations.
  • Hyperparathyroidism: Certain MEN2 subtypes can cause excessive parathyroid hormone production and elevated blood calcium.
  • Cardiovascular Complications: Unrecognized catecholamine-producing tumors may trigger severe hypertension or abnormal heart rhythms.
  • Delayed Endocrine Care: Failure to identify MEN2 may postpone genetic counseling, tumor surveillance, and preventive treatment.

Contraindication #3: Serious Allergic Reactions to GLP-1 Medications

What Is a Serious GLP-1 Allergic Reaction?

A serious GLP-1 allergic reaction is an immune-mediated response to a medication or one of its ingredients. Reactions can include anaphylaxis, a potentially life-threatening systemic allergic reaction, and angioedema, which causes swelling beneath the skin. A previous serious hypersensitivity reaction to a particular GLP-1 medication or its ingredients is an absolute contraindication to using that product again.

Potential Consequences of Taking GLP-1 Medications with This Condition

Taking a GLP-1 medication after experiencing a serious allergic reaction to the same product can trigger another severe reaction. Anaphylaxis may progress rapidly and requires emergency medical attention. Potential consequences include:

  • Throat Swelling: Angioedema may affect the tongue, throat, or airway and interfere with breathing.
  • Severe Breathing Difficulties: Airway narrowing or bronchospasm may cause wheezing and respiratory distress.
  • Dangerously Low Blood Pressure: Anaphylaxis can cause sudden circulatory collapse.
  • Loss of Consciousness: Reduced blood flow to the brain may cause fainting or unresponsiveness.
  • Life-Threatening Anaphylactic Shock: Severe allergic reactions can result in organ failure or death without prompt treatment.

Contraindication #4: Pregnancy

What Is Pregnancy?

Pregnancy is the period during which an embryo or fetus develops inside the uterus. GLP-1 medications used for weight management should not be used during pregnancy because weight loss is not recommended during pregnancy and available evidence raises concerns about potential fetal harm. Pregnancy is an important reason to discontinue these medications and discuss appropriate alternatives with a healthcare provider.

Potential Consequences of Taking GLP-1 Medications with This Condition

Continuing GLP-1 weight-management treatment during pregnancy may expose a developing fetus to medication-related risks that have not been adequately characterized in humans. Animal studies have identified reproductive and developmental concerns with certain medications. Potential consequences and safety concerns include:

  • Potential Fetal Harm: Animal reproductive studies have identified developmental risks with certain GLP-1 medications, although the human risk remains uncertain.
  • Fetal Growth Concerns: Reduced fetal growth has been observed in some animal studies involving these medications.
  • Inadequate Maternal Nutrition: Medication-related appetite suppression, nausea, or vomiting may make adequate nutritional intake more difficult.
  • Dehydration: Persistent vomiting or diarrhea can cause fluid and electrolyte losses during pregnancy.
  • Unnecessary Medication Exposure: Continuing treatment for weight loss exposes the fetus to a medication without an established pregnancy-related benefit.

Contraindication #5: Pancreatitis

What Is Pancreatitis?

Pancreatitis is inflammation of the pancreas, an organ responsible for producing digestive enzymes and hormones that regulate blood sugar. Acute pancreatitis has been reported in patients taking GLP-1 medications. A history of pancreatitis is not a universal absolute contraindication, but it requires careful medical evaluation. If acute pancreatitis is suspected during treatment, the medication should be stopped and the patient evaluated promptly.

Potential Consequences of Taking GLP-1 Medications with This Condition

Acute pancreatitis can become a medical emergency, particularly when inflammation causes tissue damage or affects other organs. Although a direct causal relationship between GLP-1 medications and pancreatitis has not been conclusively established, ignoring symptoms during treatment can delay essential care. Potential consequences include:

  • Severe Abdominal Pain: Pancreatic inflammation can cause persistent upper abdominal pain that may radiate to the back.
  • Persistent Vomiting: Pancreatitis may produce severe nausea and vomiting that interfere with hydration and nutrition.
  • Pancreatic Tissue Damage: Severe inflammation can cause pancreatic necrosis, in which portions of pancreatic tissue die.
  • Organ Failure: Severe acute pancreatitis can affect kidney, lung, and cardiovascular function.
  • Life-Threatening Complications: Severe pancreatitis may cause systemic inflammation, infection, or death.

Contraindication #6: Severe Gastroparesis

What Is Gastroparesis?

Gastroparesis is a digestive disorder in which the stomach empties food more slowly than normal without a mechanical obstruction. GLP-1 medications can further delay gastric emptying, potentially worsening symptoms. Severe gastroparesis is an important prescribing precaution, and several GLP-1 medications are not recommended for patients with this condition.

Potential Consequences of Taking GLP-1 Medications with This Condition

Patients with severe gastroparesis may experience worsening digestive symptoms when taking medications that slow gastric emptying. Persistent symptoms can interfere with nutrition, hydration, and medication absorption. Potential consequences include:

  • Persistent Nausea: Delayed stomach emptying can cause ongoing nausea, especially after meals.
  • Recurrent Vomiting: Food remaining in the stomach for prolonged periods may contribute to repeated vomiting.
  • Severe Abdominal Discomfort: Patients may experience bloating, upper abdominal pain, and uncomfortable fullness.
  • Malnutrition: Difficulty tolerating adequate meals can lead to insufficient calorie and nutrient intake.
  • Dehydration and Electrolyte Imbalances: Repeated vomiting and inadequate fluid intake may disrupt normal hydration and electrolyte levels.

Contraindication #7: Gallbladder Disease

What Is Gallbladder Disease?

Gallbladder disease refers to conditions affecting the gallbladder, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis). GLP-1 treatment and substantial weight loss may be associated with an increased risk of gallbladder complications. Existing gallbladder disease is not generally an absolute contraindication, but symptoms or a relevant medical history warrant evaluation.

Potential Consequences of Taking GLP-1 Medications with This Condition

Unrecognized gallbladder disease can progress from intermittent abdominal discomfort to serious inflammation or obstruction. Patients taking GLP-1 medications who develop persistent upper abdominal pain, particularly with fever or jaundice, require medical evaluation. Potential consequences include:

  • Gallstone Attacks: Gallstones may obstruct bile flow and cause sudden, intense upper abdominal pain.
  • Acute Cholecystitis: Gallbladder inflammation can cause persistent pain, fever, and tenderness.
  • Bile Duct Obstruction: Gallstones entering the bile ducts can interfere with bile drainage and cause jaundice.
  • Gallstone Pancreatitis: A gallstone blocking the pancreatic drainage pathway may trigger acute pancreatitis.
  • Gallbladder Infection: Untreated obstruction and inflammation may lead to serious infection requiring hospitalization or surgery.

Contraindication #8: Kidney Problems and Severe Dehydration

What Are Kidney Problems and Severe Dehydration?

Kidney problems involve impaired kidney function, while severe dehydration occurs when the body loses more fluid than it can replace. GLP-1 medications may cause nausea, vomiting, or diarrhea that leads to dehydration and acute kidney injury. Chronic kidney disease is not automatically a contraindication to every GLP-1 medication, but patients with impaired kidney function or significant fluid loss may require closer monitoring.

Potential Consequences of Taking GLP-1 Medications with This Condition

Persistent dehydration can reduce blood flow to the kidneys and contribute to acute kidney injury. Patients with existing kidney disease may be particularly vulnerable to complications from substantial fluid loss. Potential consequences include:

  • Acute Kidney Injury: Reduced kidney blood flow can cause a sudden decline in the kidneys’ ability to filter waste.
  • Electrolyte Imbalances: Fluid losses and impaired kidney function may disrupt sodium, potassium, and other electrolyte levels.
  • Low Blood Pressure: Severe dehydration can reduce circulating blood volume and cause dizziness or fainting.
  • Worsening Kidney Function: Patients with preexisting kidney impairment may experience additional deterioration during dehydration-related illness.
  • Hospitalization: Severe dehydration or acute kidney injury may require intravenous fluids, laboratory monitoring, or inpatient treatment.

Contraindication #9: Hypoglycemia Risk With Other Diabetes Medications

What Is Hypoglycemia?

Hypoglycemia is an abnormally low blood glucose level, generally defined as below 70 mg/dL in people with diabetes. GLP-1 medications have a relatively low risk of causing hypoglycemia when used alone, but combining them with insulin or sulfonylureas can increase that risk. This drug combination is not automatically contraindicated, although medication adjustments and glucose monitoring may be necessary.

Potential Consequences of Taking GLP-1 Medications with This Condition

Severe hypoglycemia can interfere with normal brain function because glucose is an essential energy source for the brain. Patients taking GLP-1 medications alongside insulin or insulin-releasing drugs may require dosage adjustments to prevent dangerous blood sugar reductions. Potential consequences include:

  • Shaking and Sweating: Falling blood sugar can activate the body’s stress response, causing tremors, sweating, and palpitations.
  • Confusion: Inadequate glucose delivery to the brain may impair concentration, judgment, and coordination.
  • Loss of Consciousness: Severe hypoglycemia may cause fainting or an inability to respond normally.
  • Seizures: Extremely low blood glucose can disrupt brain activity and trigger seizures.
  • Hypoglycemic Coma: Prolonged, severe hypoglycemia can cause coma and potentially permanent neurological injury.

Contraindication #10: Diabetic Retinopathy

What Is Diabetic Retinopathy?

Diabetic retinopathy is an eye disease caused by damage to retinal blood vessels associated with diabetes. Rapid improvements in blood glucose levels can sometimes temporarily worsen existing diabetic retinopathy. Patients with a history of diabetic retinopathy may require additional eye monitoring when starting certain GLP-1 medications. Diabetic retinopathy is not generally an absolute contraindication to GLP-1 treatment.

Potential Consequences of Taking GLP-1 Medications with This Condition

Patients with existing diabetic retinopathy may experience worsening retinal disease during periods of rapid blood sugar improvement, making appropriate eye monitoring important. These complications are consequences of diabetic retinopathy itself and are not all established direct effects of GLP-1 medications. Potential consequences include:

  • Blurred Vision: Retinal swelling or changes in blood vessels may reduce visual clarity.
  • Macular Edema: Fluid accumulation in the central retina can impair detailed vision.
  • Retinal Hemorrhage: Damaged retinal blood vessels may leak or bleed into surrounding tissue.
  • Retinal Detachment: Advanced proliferative diabetic retinopathy can cause scar tissue that pulls the retina away from its normal position.
  • Permanent Vision Loss: Advanced or untreated diabetic retinopathy may result in irreversible visual impairment or blindness.